$ENGN
enGene Therapeutics Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Saint-Laurent
ENGN chart
What traders are saying about $ENGN
Latest postsenGene Therapeutics Inc. news
- enGene Therapeutics Inc. Estimates – NASDAQ:ENGN
TradingView ·
- enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path
marketbeat.com ·
- enGene to Host KOL Webinar on October 15, 2026
Yahoo Finance ·
- enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
Yahoo Finance ·
- enGene to Participate in Upcoming Investor Conferences
Yahoo Finance ·
- enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market
marketbeat.com ·
- enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
Yahoo Finance ·
- enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
Yahoo Finance ·
- Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
Yahoo Finance ·
- Neumora depression drug fails; EnGene to cut 50% of staff
biopharmadive.com ·
- enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
Yahoo Finance ·
- A Look At enGene Therapeutics (ENGN) Valuation After LEGEND Trial Update And Legal Investigations
Yahoo Finance ·
enGene Therapeutics Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$117.3M | -$55.1M | -$99.9M | -$24.5M |
| Diluted EPS | $2.29 | $1.46 | $151.22 | $44.30 |
| Total assets (year end) | $337.1M | $285.9M | $93.4M | – |
| Cash and equivalents (year end) | $36.6M | $62.3M | $85.6M | – |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About enGene Therapeutics Inc.
- Ticker
- ENGN (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Saint-Laurent
- Incorporated in
- Canada (Federal Level)
- Fiscal year end
- October 31
- SEC CIK
- 1980845
- Former names
- enGene Holdings Inc.
Frequently asked questions
What exchange is enGene Therapeutics Inc. listed on?
enGene Therapeutics Inc. trades on the Nasdaq under the ticker symbol ENGN.
What industry is enGene Therapeutics Inc. in?
enGene Therapeutics Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is enGene Therapeutics Inc. headquartered?
enGene Therapeutics Inc.'s business address on file with the SEC is in Saint-Laurent.
When does enGene Therapeutics Inc.'s fiscal year end?
enGene Therapeutics Inc.'s fiscal year ends on October 31.